kisqali tablets film-coated
novartis pharma produktions gmbh - ribociclib(ribociclib succinate) - tablets film-coated - 200mg
alecensa capsules hard
f. hoffmann-la roche ag - alectnib (alectinib hydrochloride) - capsules hard - 150mg
lenvima
eisai europe ltd - lenvatinib mesylate - thyroid neoplasms - antineoplastic agents - lenvima is indicated for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/hürthle cell) thyroid carcinoma (dtc), refractory to radioactive iodine (rai).
imatinib rowex 100mg film-coated tablets
rowex ltd - imatinib mesilate - film-coated tablet - 100 milligram(s) - protein kinase inhibitors; imatinib - protein-tyrosine kinase inhibitor - paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult patients with ph+ cml in blast crisis. adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement. adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurre
imatinib rowex 400mg film-coated tablets
rowex ltd - imatinib mesilate - film-coated tablet - 400 milligram(s) - protein kinase inhibitors; imatinib - protein-tyrosine kinase inhibitor - paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult patients with ph+ cml in blast crisis. adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement. adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurre
imatinib 100 mg film-coated tablets
fresenius kabi deutschland gmbh - imatinib mesilate - film-coated tablet - 100 milligram(s) - protein kinase inhibitors; imatinib
imatinib 400 mg film-coated tablets
fresenius kabi deutschland gmbh - imatinib mesilate - film-coated tablet - 400 milligram(s) - protein kinase inhibitors; imatinib
imatinib krka d.d 100 mg film-coated tablets
krka, d.d., novo mesto - imatinib mesilate - film-coated tablet - 100 milligram(s) - protein kinase inhibitors; imatinib
imatinib krka d.d. 400 mg film-coated tablets
krka, d.d., novo mesto - imatinib mesilate - film-coated tablet - 400 milligram(s) - protein kinase inhibitors; imatinib
everolimus teva 5 mg tablets
teva b.v. - everolimus - tablet - 5 milligram(s) - protein kinase inhibitors; imatinib